Forward-looking statements This presentation contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding Embecta Corp.'s ("embecta's") future prospects and perform

Mission To develop and provide

solutions that make life better for people living with diabetes Vision A life unlimited by diabetes Advance every day together Investor Presentation March 7, 2022 Exhibit 99.1

Forward-looking statements This

presentation contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding Embecta Corp.'s ("embecta's") future prospects and performance, including, but not limited to,

future revenues, margins, leverage targets, and capital deployment, including strategies of embecta following the proposed spinoff, the anticipated benefits of the spinoff, and the expected timing of completion of the spinoff. Forward-looking

statements include those containing such words as "anticipate," "believes," "could," "estimates," "expects," "goal," "intends," "may,"

"seeks," "targets," "will," "would," or other similar words. All such statements are based upon current expectations of embecta and involve a number of business risks and uncertainties. Actual results

could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These

factors include, but are not limited to, risks relating to any impact of the current disruptions in the global supply chain on our operations, including our ability to source raw materials and components needed to manufacture our products and

inflationary pressures; the impact of the COVID-19 pandemic on our business (including decreases in the demand for our products or any disruptions to our operations and our supply chain); product efficacy or safety concerns resulting in product

recalls or actions being taken with respect to our products; new or changing laws and regulations impacting our business (including the imposition of tariffs, changes in tax laws, new environmental laws and regulations, or changes in laws impacting

international trade) or changes in enforcement practices with respect to such laws; fluctuations in costs and availability of raw materials, labor shortages or increased labor costs and embecta's ability to maintain favorable supplier

arrangements and relationships; legislative or regulatory changes to the U.S. or foreign healthcare systems, potential cuts in governmental healthcare spending or governmental or private measures to contain healthcare costs, including changes in

pricing and reimbursement policies, each of which could result in reduced demand for our products or downward pricing pressure; changes in interest or foreign currency exchange rates; adverse changes in regional, national or foreign economic

conditions, including inflation, deflation and fluctuations in interest rates, particularly in emerging markets, including any impact on our ability to access credit markets and finance our operations; the demand for our products and services, or

our suppliers' ability to provide products needed for our operations; the adverse impact of cyber-attacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; risks

related to our overall indebtedness; interruptions in our supply chain, manufacturing or sterilization processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market

acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing embecta's products; our ability to achieve our projected level or mix of product

sales; our ability to successfully integrate any businesses we acquire; issuance of new or revised accounting standards; risks associated with the spinoff from Becton Dickinson ("BD"), including factors that could delay, prevent or

otherwise adversely affect the completion, timing or terms of the spin-off, our ability to realize the expected benefits of the spin-off, or the qualifications of the spin-off as a tax-free transaction for U.S. federal income tax purposes, as well

as other factors discussed in BD's filings with the Securities and Exchange Commission. There can be no assurance that the spinoff will in fact be completed in the manner described or at all. We do not intend to update any forward-looking

statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Presenters Joined BD February 2021 and

currently serves as Worldwide President, BD Diabetes Care Served as CEO and president for Cardiac Science until the sale of the company General manager for the men's health business at Boston Scientific and American Medical Systems (AMS) Also

held positions of increasing responsibility and leadership with Baxter International Holds MBA from Washington University in St. Louis and a Ph.D. in Chemical Engineering from Purdue University Currently a member of the Board of Directors of LMG

Holdings Joined BD May 2021 and currently serves as SVP, Finance, Diabetes Care Extensive experience in accounting, treasury, financial planning, reporting and analysis, and investor relations Most recently served as Treasurer and VP of Investor

Relations at Teleflex Incorporated Spent 10 years at Motorola and 4 years at PwC Holds B.S. in Accounting from the University of Scranton and an MBA in Finance from St. Joseph's University Dev Kurdikar Chief Executive Officer of embecta Jake

Elguicze Chief Financial Officer of embecta

Discussion Topics Topic Presenter

Welcome Dev Kurdikar Overview of embecta The global diabetes landscape embecta's position of strength Immediate benefits of the spin Global growth opportunities Dev Kurdikar Financial overview

Jake Elguicze Q&A All

An expanding category Pure-play

diabetes company with leadership in insulin delivery Diabetes: chronic condition, large and growing market opportunity Strong, trusted core business Established brand loyalty over ~100 years Unmatched global manufacturing infrastructure and know-how

Geographically diverse sales and distribution network Immediate benefits of the spin Compelling financial profile that supports an "invest for growth" strategy Attract talent; proven leadership and highly motivated workforce Streamlined

operating model: more nimble, innovative, and customer-focused Opportunities for growth Deliver organic growth R&D pipeline with potential to enter infusion segment M&A and partnership opportunities embecta's strong position after the

spin Our stable core provides the foundation for new growth opportunities

Overview of embecta 1. The global

diabetes landscape A growing space defined by lifelong treatment 2. embecta's enduring position of strength Trusted leader with best-in-class products and unmatched capabilities 3. Why the spin creates a stronger embecta at day 1 Strong core

provides basis for growth - led by a world-class team 4. Reinvesting in ourselves to pursue global growth opportunities Spanning organic, R&D, and M&A

Overview of embecta 1. The global

diabetes landscape A growing space defined by lifelong treatment 2. embecta's enduring position of strength Trusted leader with best-in-class products and unmatched capabilities 3. Why the spin creates a stronger embecta at day 1 Strong core

provides basis for growth - led by a world-class team 4. Reinvesting in ourselves to pursue global growth opportunities Spanning organic, R&D, and M&A

Prevalence of diabetes is steadily and

consistently rising: Rates of diagnosis, treatment, and care are rising, especially in emerging markets, due to changing demographics, lifestyle factors, and increased access to care. Diabetes requires chronic, lifelong treatment: Once on insulin

intensive therapy, PWD remain dependent on the medicine for the remainder of their lives. Standard of care persists, while unmet needs create opportunities: As the category grows, insulin injections will remain the standard of care. But PWD want

innovations and improvements in their care experiences. The global diabetes landscape A growing space where people with diabetes (PWD) need chronic treatment

Notes: IDF, Diabetes Atlas, 10th

Edition. (1) Figures indicate the number of people with diabetes in millions. Prevalence and cost of diabetes Growing consistently around the world Prevalence 1 in 10 adults have diabetes 3 in 4 people with diabetes live in low- and middle-income

countries Total (MM) (1) 537 783 2021 2045 46% +246M Cost of diabetes $966B, 10% of global health expenditures, is attributed to diabetes Has increased by 316% over the past 15 years 51 63 2021 2045 24% North America & Caribbean (MM)(1) 32 49

2021 2045 50% South & Central America (MM) (1) 90 152 2021 2045 Southeast Asia (MM) (1) 68% Western Pacific (MM) (1) 206 260 2021 2045 27% Europe (MM) (1) 61 69 2021 2045 13% 73 136 2021 2045 Middle East & North Africa (MM) (1) 87% 2021 2045

Africa (MM) (1) 134% 24 55

Trajectory Commentary Total base population Total number of people in emerging markets Based on pace of underlying population growth Prevalence rate Percentage of total population with diabetes Increasing due to dietary shifts, urbanization, and

increasing life expectancies Diabetes diagnosis rate Percentage of PWD diagnosed Increasing due to greater access to medical care and increased diabetes awareness Insulin treatment rate Percentage of diagnosed PWD treated with insulin Increasing

along with economic growth and availability / acceptance of less expensive biosimilar insulin Injection-Based Administration (IBA) Percentage of insulin-treated PWD with injection-based administration (vs. pump) Flat IBA utilization rate given very

low access to / coverage of pumps Diabetes in emerging markets Increases in prevalence, diagnosis, and treatment rates Notes: IDF, Diabetes Atlas, 10th Edition. DRG Patient Data; DRG Product Data.

Life-long dependence on insulin for

PWD Type 1 start on insulin at diagnosis; Type 2 progress to insulin dependency Notes: IDF, Diabetes Atlas, 10th Edition. ADA. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Based on internal

management estimates. Type 1 diabetes (T1D) Type 2 diabetes (T2D) T2D occurs when the body doesn't produce enough insulin or is resistant to insulin Inadequate production of insulin can develop as a result of failure of the pancreatic beta

cells to keep up with demand Basal + Bolus Insulin Insulin Infusion Orals GLP-1s Basal Insulin Only Basal + Bolus Insulin Insulin Infusion Diet & Exercise T1D is caused by an autoimmune process that attacks pancreatic beta-cells that produce

insulin T1 PWD require insulin to survive: Start basal and bolus insulin therapy immediately On average, inject insulin >4 times a day Typical use is 0.5-1 u/kg/day use T1 PWD: ~28M T2 PWD (diagnosed): ~280M (~40-65M on insulin; ~15M-25M are

insulin intensive) Typical Treatments For T2 PWD, therapeutic regimens change over time to accommodate worsening glycemic control: Average >10 years from diagnosis to start insulin Most eventually require insulin therapy Use can vary; many use up

to 100 U of insulin/day (those on basal and bolus insulin therapy)

As diagnosis and treatment reaches

more PWD, insulin treatment likely to be via injection. Notes: Based on internal management estimates Pump penetration(1) over the next decade is expected to reach ~55-60% for T1 PWD and ~20-25% for T2 insulin-intensive PWD. Cost: injection <<

pump Avoid "wearing the disease" Simplicity of injection vs. pump technology Sufficient control achieved Injections are expected to remain the standard of care Across developed markets and emerging markets Developed markets Emerging

markets Reasons majority of PWD will administer insulin via injection:

Treatment adherence Must serve as

own healthcare provider: Monitoring, making decisions, and completing healthcare tasks that reach into every aspect of daily life Self-monitoring PWD must continuously monitor blood glucose levels and consider implications for activities, decisions,

and treatment each day. PWD must manage medications and adhere to treatment requirements. PWD must make this calculation based on daily diet, exercise, and other lifestyle factors. PWD must make daily decisions about what and when to eat, whether to

exercise, and treatment. Daily decisions PWD must make and manage lifestyle changes, including exercise, diet, smoking cessation, and sleep. Lifestyle changes High burden with impacts on physical health, finances, and mental well-being. Unmet needs

remain, even with the most advanced treatments Insulin-dependent PWD face complex burden & daily challenges

Overview of embecta 1. The global

diabetes landscape A growing space defined by lifelong treatment 2. embecta's enduring position of strength Trusted leader with best-in-class products and unmatched capabilities 3. Why the spin creates a stronger embecta at day 1 Strong core

provides basis for growth - led by a world-class team 4. Reinvesting in ourselves to pursue global growth opportunities Spanning organic, R&D, and M&A

Trusted leader in the global

marketplace: The largest producer of diabetes injection devices with a ~100-year history of reliability and quality. Best-in-class products and brand: Trusted brand leadership across our broad portfolio for PWD in all geographies. Unmatched

manufacturing, distribution and sales capabilities: Produce ~7.6B units and distribute to 100+ countries and ~30M PWD. embecta's enduring strengths Trusted leader with best-in-class products and unmatched capabilities

2009 2011 2012 2012 2013 2018 2018

BD's smallest and thinnest pen needle: 4mm x 32G BD AutoShield Duo , first safety pen needle with dual protective shield First five-bevel needle: Pentapoint BD's shortest insulin syringe needle: 6mm BD introduces

EasyFlow technology Launch of BD Diabetes Care App Introduction of BD NanoTM 2nd Gen 4mm Pen Needles 1897 1924 1952 1969 1988 1991-1999 1997 2003 A decisive handshake between Maxwell Becton and Fairleigh Dickinson First insulin

syringe for insulin injection therapy First "disposable" insulin syringe First "self contained" insulin syringe New needle lubrication Pen needle introduction makes insulin delivery more discreet and portable First short

insulin syringe "8mm" Thin wall technology introduced PORTFOLIO EVOLUTION PORTFOLIO EVOLUTION A long history and rich heritage in diabetes Nearly 100 years of quality, trust, and innovation Note: Brand names may vary by region

embecta by the numbers(1) embecta is

a leader in the global marketplace Our strong core business reaches PWD around the world ~2,000 #1 ~7.6B ~30M Producer of diabetes injection devices Units produced annually across 3 world-class facilities ~65% >100 600+ $1.16B PF FY'21

gross margin (2) Countries served FY'21 revenue ~41% PF FY'21 Adjusted EBITDA margin(2) Employees globally PWD reached annually Commercially focused employees Notes: (1) Based on SEC filings and internal management estimates. (2) See

reconciliation in appendix

Notes: (1) Based on internal

management estimates of total unit volumes. Leadership across the injection platform Segment leadership in multiple product categories Pen Needles #1 Globally(1) Syringes #1 Globally(1) Safety #1 Globally(1) BD SafetyGlideTM BD AutoShield DuoTM

Conventional Syringes BD Nano 2nd Gen.TM Conventional and BD NanoTM

Select competitors Pen needle

portfolio Strategic focus ~50% SOC +0.6% vs. LY Demonstrate clinical leadership -- increase awareness regarding injection technique Drive differentiation and share of category (SOC) growth through Nano 2nd gen Global expansion of Nano 2nd gen into

new segments Future pen needle portfolio expansion to address key customer and market needs embecta is the #1 brand in the growing pen needle category Based on strong legacy, clinical leadership, and customer loyalty Comprehensive portfolio of

needle lengths (4mm, 5mm, 6mm, 8mm, 12.7mm) Innovation in category through Nano 2nd gen and contoured hub design to drive more reliable injection depth Pentapoint comfort technology, with a 5-bevel needle tip, helps give a more comfortable

injection experience EasyFlow technology, with extra-thin wall design, helps to provide an easier injection experience and allows for faster administration of insulin Compatible with the majority of insulin injection pens Novo Nordisk

HTL-Strefa Terumo Medical Corporation Ypsomed

~50% SOC +0.6% vs. LY embecta is #1

in insulin syringes Poised to take advantage of shift to pen needles Select competitors Syringe portfolio Strategic focus Local manufacturers Position syringes with pen needle portfolio as single injection delivery partner Demonstrate clinical

leadership - increasing awareness regarding injection technique Optimize portfolio to increase operational efficiencies Full portfolio of needle lengths (6mm, 8mm 12.7mm) with strategic focus on driving to shorter needle lengths Variety of

barrel sizes (0.3mL, 0.5mL, 1mL) to allow for greater dose accuracy based on patient's insulin dose Portfolio of insulin syringes designed for use with different insulin strengths: U-100, U-500, and U-40 to ensure correct insulin dosing

Insulin syringes are marked in units (as that is how insulin is dosed); largest barrel size is 1mL (generally smaller than hypodermic syringes)